Recurrent Atypical Hemolytic Uremic Syndrome Post-Renal Transplantation: Case Report Treated with Eculizumab

Atypical Hemolytic Uremic syndrome is disease that could results in end stage renal disease and subsequently requiring hemodialysis or renal transplant. It also could recur after renal transplant, which poses a challenge to diagnose and treat given the complexity of immunosuppressive medications. Proper preparation before the transplant and vigilant post transplant monitoring is crucial to preserve the precious graft and start the appropriate treatment promptly at recurrence. Eculizumab has been used in atypical Hemolytic Uremic syndrome. We report a case of recurrent atypical Hemolytic Uremic syndrome post renal transplant that was refractory to plasma exchange and showed excellent response to Eculizumab.